OSUR
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure\'s portfolio of products is sold globally to clinical laboratories, hospitals, physician\'s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers.
OraSure Technologies, Inc. (OSUR) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (3.0) | C (2.3) | B- (3.0) | B (3.5) | C+ (2.6) | B- (2.9) |
| 2026-11-07 | B- (3.0) | C (2.2) | B- (3.0) | B (3.2) | C+ (2.7) | C+ (2.8) |
| 2026-10-31 | B- (3.0) | C- (2.1) | B- (3.0) | B (3.3) | C+ (2.7) | C+ (2.8) |
| 2026-10-24 | B- (3.0) | C- (2.1) | B- (3.0) | B (3.3) | C+ (2.6) | C+ (2.8) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe